Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vicinalizumab
- Development stage
- Unknown
- Lead developer
- Sun Yat-sen University Cancer Center
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravesical
01
Overview
Vicinalizumab is a humanized monoclonal antibody that targets the Human Epidermal Growth Factor Receptor 2 (HER2). Developed by the Sun Yat-sen University Cancer Center, it is primarily utilized as a targeting ligand in the construction of diagnostic nanocomposites, such as gold nanostar-vicinalizumab (AuNS@DV). These nanocomposites are designed for the non-invasive, in situ detection of non-muscle-invasive bladder cancer (NMIBC) using Surface-Enhanced Raman Scattering (SERS) technology. By binding specifically to HER2-expressing tumor cells, vicinalizumab facilitates the localization of gold nanostars to the tumor site, which then amplify Raman signals to provide high-sensitivity diagnostic imaging of bladder lesions.
- Other names
- vicinalizumab
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on vicinalizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vicinalizumab.